Back to News
Market Impact: 0.3
Novo's Sogroya Gets Positive EU Opinion For Children With Idiopathic Short Stature
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Novo Nordisk said the EMA's CHMP recommended approval of once-weekly Sogroya (somapacitan) for children with idiopathic short stature and persistent growth disorders. The positive regulatory opinion could expand Sogroya's pediatric addressable market in Europe, subject to final European Commission approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
NVO0.55
More News
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Anthropic is operating a lab that conducts biology experiments
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- India forces caller-ID apps to feed spam reports to telcos